The synergistic anticancer effect of troglitazone combined with aspirin causes cell cycle arrest and apoptosis in human lung cancer cells

Molecular Carcinogenesis

Volumn 49, Issue 3, 2010, Pages 235-246

  Yan, Kun Huang ^a,b   Yao, Chih Jung ^b,d   Chang, Hwan You ^a   Lai, Gi Ming ^b,d   Cheng, Ann Lii ^c   Chuang, Shuang En ^b  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Aspirin; NSAID; Ppar ; Synergy; Troglitazone

Indexed keywords

ACETYLSALICYLIC ACID; CASPASE 3; CYCLIN B1; CYCLIN D3; CYCLIN DEPENDENT KINASE 2; PROTEIN KINASE B; PROTEIN P27; RAC1 PROTEIN; TRANSCRIPTION FACTOR E2F1; TROGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTINEOPLASTIC AGENT; CHROMAN DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; CELL CYCLE; CELL PROLIFERATION; CLONOGENIC ASSAY; DRUG COMBINATION; DRUG EFFECT; FLOW CYTOMETRY; LUNG TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; ASPIRIN; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; CHROMANS; COLONY-FORMING UNITS ASSAY; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FLOW CYTOMETRY; HUMANS; LUNG NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; PPAR GAMMA; THIAZOLIDINEDIONES; TUMOR CELLS, CULTURED;

EID: 77949878222     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20593     Document Type: Article

References (68)

1. Jalving M, Koornstra JJ, De Jong S, De Vries EG, Kleibeuker JH. Review article: The potential of combinational regimen with non-steroidal anti-inflammatory drugs in the chemoprevention of colorectal cancer. Aliment Pharmacol Ther 2005;21:321-339. (Pubitemid 40313936)
2. Keshamouni VG, Reddy RC, Arenberg DA, et al. Peroxisome proliferator-activated receptor-gamma activation inhibits tumor progression in non-small-cell lung cancer. Oncogene 2004;23:100-108.
3. Chang TH, Szabo E. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer. Cancer Res 2000;60:1129-1138. (Pubitemid 30129556)
4. Feinstein DL, Spagnolo A, Akar C, et al. Receptor-independent actions of PPAR thiazolidinedione agonists: Is mitochondrial function the key? Biochem Pharmacol 2005;70:177-188.
5. Satoh T, Toyoda M, Hoshino H, et al. Activation of peroxisome proliferator-activated receptor-gamma stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cells. Oncogene 2002;21:2171-2180. (Pubitemid 34311371)
6. Han S, Sidell N, Fisher PB, Roman J. Up-regulation of p21 gene expression by peroxisome proliferator-activated receptor gamma in human lung carcinoma cells. Clin Cancer Res 2004;10:1911-1919. (Pubitemid 38375547)
7. Smith MT. Mechanisms of troglitazone hepatotoxicity. Chem Res Toxicol 2003;16:679-687.
8. Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N Engl J Med 1998;338:916-917.
9. Wang PS, Chou FS, Porchia L, Saji M, Pinzone JJ. Troglitazone inhibits cell migration, adhesion, and spreading by modulating cytoskeletal rearrangement in human breast cancer cells. Mol Carcinog 2008;47:905-915.
10. Baek SJ, Wilson LC, Hsi LC, Eling TE. Troglitazone, a peroxisome proliferator-activated receptor gamma (PPAR gamma) ligand, selectively induces the early growth response-1 gene independently of PPAR gamma. A novel mechanism for its anti-tumorigenic activity. J Biol Chem 2003;278:5845-5853.
11. Chaffer CL, Thomas DM, Thompson EW, Williams ED. PPARgamma-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma. BMC Cancer 2006;6:53.
12. Moysich KB, Menezes RJ, Ronsani A, et al. Regular aspirin use and lung cancer risk. BMC Cancer 2002;2:31. (Pubitemid 38851290)
13. Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 2001;15:2057-2072.
14. di Palma A, Matarese G, Leone V, et al. Aspirin reduces the outcome of anticancer therapy in Meth A-bearing mice through activation of AKT-glycogen synthase kinase signaling. Mol Cancer Ther 2006;5:1318-1324. (Pubitemid 43881325)
15. Abdin AA, Baalash AA, Hamooda HE. Effects of rosiglitazone and aspirin on experimental model of induced type 2 diabetes in rats: Focus on insulin resistance and inflammatory markers. J Diabetes Complications 2009 [Epub ahead of print].
16. Cui X, Yang SC, Sharma S, Heuze-Vourc'h N, Dubinett SM. IL-4 regulates COX-2 and PGE2 production in human non-small cell lung cancer. Biochem Biophys Res Commun 2006;343:995-1001.
17. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998;58:362-366. (Pubitemid 28047080)
18. Hazra S, Batra RK, Tai HH, Sharma S, Cui X, Dubinett SM. Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase. Mol Pharmacol 2007;71:1715-1720. (Pubitemid 47010924)
19. Borthwick GM, Johnson AS, Partington M, Burn J, Wilson R, Arthur HM. Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Cox-independent mechanism. FASEB J 2006;20:2009-2016. (Pubitemid 44953901)
20. Elder DJ, Paraskeva C. COX-2 inhibitors for colorectal cancer. Nat Med 1998;4:392-393.
21. Brenner DE, Gescher AJ. Cancer chemoprevention: Lessons learned and future directions. Br J Cancer 2005;93:735-739. (Pubitemid 41486430)
22. Stark LA, Reid K, Sansom OJ, et al. Aspirin activates the NF-kappaB signalling pathway and induces apoptosis in intestinal neoplasia in two in vivo models of human colorectal cancer. Carcinogenesis 2007;28:968-976. (Pubitemid 47072180)
23. Kim CH, Kim MY, Moon JY, et al. Implication of NAG-1 in synergistic induction of apoptosis by combined treatment of sodium salicylate and PI3K/MEK1/2 inhibitors in A549 human lung adenocarcinoma cells. Biochem Pharmacol 2008;75:1751-1760.
24. Shaik MS, Chatterjee A, Jackson T, Singh M. Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors. Int J Cancer 2006;118:396-404. (Pubitemid 41779079)
25. Xing L, Zhang Z, Xu Y, Zhang H, Liu J. The effects of nimesulide combined with cisplatin on lung cancer. J Huazhong Univ Sci Technol Med Sci 2004;24:120-123. (Pubitemid 41559649)
26. Gately S, Kerbel R. Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis. Prog Exp Tumor Res 2003;37:179-192. (Pubitemid 36767986)
27. Yu J, Qiao L, Zimmermann L, et al. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo. Hepatology 2006;43:134-143. (Pubitemid 43733600)
28. Liu JJ, Liu PQ, Lin DJ, et al. Downregulation of cyclooxygenase-2 expression and activation of caspase-3 are involved in peroxisome proliferator-activated receptor-gamma agonists induced apoptosis in human monocyte leukemia cells in vitro. Ann Hematol 2007;86:173-183.
29. Yang WL, Frucht H. Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells. Carcinogenesis 2001;22:1379-1383. (Pubitemid 32898693)
30. Subbaramaiah K, Lin DT, Hart JC, Dannenberg AJ. Peroxisome proliferator-activated receptor gamma ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300. J Biol Chem 2001;276:12440-12448. (Pubitemid 37385418)
31. Lee KS, Park JH, Lee S, Lim HJ, Jang Y, Park HY. Troglitazone inhibits endothelial cell proliferation through suppression of casein kinase 2 activity. Biochem Biophys Res Commun 2006;346:83-88. (Pubitemid 43865970)
32. Goetze S, Bungenstock A, Czupalla C, et al. Leptin induces endothelial cell migration through Akt, which is inhibited by PPARgamma-ligands. Hypertension 2002;40:748-754.
33. Goetze S, Eilers F, Bungenstock A, et al. PPAR activators inhibit endothelial cell migration by targeting Akt. Biochem Biophys Res Commun 2002;293:1431-1437.
34. Colleselli D, Bijuklic K, Mosheimer BA, Kahler CM. Inhibition of cyclooxygenase (COX)-2 affects endothelial progenitor cell proliferation. Exp Cell Res 2006;312:2933-2941.
35. Yao CJ, Lai GM, Chan CF, Cheng AL, Yang YY, Chuang SE. Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone. Int J Cancer 2006;118:773-779.
36. Chu YW, Yang PC, Yang SC, et al. Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. Am J Respir Cell Mol Biol 1997;17:353-360.
37. Keepers YP, Pizao PE, Peters GJ, van Ark-Otte J, Winograd B, Pinedo HM. Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur J Cancer 1991;27:897-900.
38. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006;58:621-681.
39. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
40. Loi CM, Young M, Randinitis E, Vassos A, Koup JR. Clinical pharmacokinetics of troglitazone. Clin Pharmacokinet 1999;37:91-104.
41. Insel PA, Herman JG, Molinoff PB, Rudden RW, Gilman AG. The pharmacological basis of therapeutics. New York: McGraw-Hill; 1996. 617 p.
42. Frantz B, O'Neill EA. The effect of sodium salicylate and aspirin on NF-kappa B. Science 1995;270:2017-2019.
43. Kwon T, Kwon DY, Chun J, Kim JH, Kang SS. Akt protein kinase inhibits Rac1-GTP binding through phosphorylation at serine 71 of Rac1. J Biol Chem 2000;275:423-428.
44. Zhang QG, Wang XT, Han D, Yin XH, Zhang GY, Xu TL. Akt inhibits MLK3/JNK3 signaling by inactivating Rac1: A protective mechanism against ischemic brain injury. J Neurochem 2006;98:1886-1898.
45. Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome proliferator-activated receptor-gamma agonists. Lancet Oncol 2004;5:419-429.
46. Rumi MA, Ishihara S, Kadowaki Y, et al. Peroxisome proliferator-activated receptor gamma-dependent and -independent growth inhibition of gastrointestinal tumour cells. Genes Cells 2004;9:1113-1123.
47. Yoshida K, Tanabe K, Fujii D, Oue N, Yasui W, Toge T. Induction mechanism of apoptosis by troglitazone through peroxisome proliferator-activated receptor-gammain gastric carcinoma cells. Anticancer Res 2003;23:267-273.
48. Verheugt FW. Aspirin, the poor man's statin? Lancet 1998;351:227-228.
49. Pawelczyk T, Kloszewska I, Sobow T. Statins - "21st century aspirin"? Pol Merkuriusz Lek 2005;19:111-114.
50. Sanchez-Alcazar JA, Bradbury DA, Pang L, Knox AJ. Cyclooxygenase (COX) inhibitors induce apoptosis in non-small cell lung cancer through cyclooxygenase independent pathways. Lung Cancer 2003;40:33-44.
51. Elwood PC, Gallagher AM, Duthie GG, Mur LA, Morgan G. Aspirin, salicylates, and cancer. Lancet 2009;373:1301-1309.
52. Alfonso LF, Srivenugopal KS, Arumugam TV, Abbruscato TJ, Weidanz JA, Bhat GJ. Aspirin inhibits camptothecin-induced p21CIP1 levels and potentiates apoptosis in human breast cancer cells. Int J Oncol 2009;34:597-608.
53. Boncler M, Gresner P, Nocun M, et al. Elevated cholesterol reduces acetylsalicylic acid-mediated platelet acetylation. Biochim Biophys Acta 2007;1770:1651-1659.
54. Chen YC, Shen SC, Tsai SH. Prostaglandin D(2) and J(2) induce apoptosis in human leukemia cells via activation of the caspase 3 cascade and production of reactive oxygen species. Biochim Biophys Acta 2005;1743:291-304.
55. McInnes C. Progress in the evaluation of CDK inhibitors as anti-tumor agents. Drug Discov Today 2008;13:875-881.
56. Duronio V. The life of a cell: Apoptosis regulation by the PI3K/PKB pathway. Biochem J 2008;415:333-344.
57. Sheng S, Qiao M, Pardee AB. Metastasis and AKT activation. J Cell Physiol 2009;218:451-454.
58. Kim J, Jonasch E, Alexander A, et al. Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma. Clin Cancer Res 2009;15:81-90.
59. Uruno A, Sugawara A, Kudo M, Satoh F, Saito A, Ito S. Stimulatory effects of low-dose 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor fluvastatin on hepatocyte growth factor-induced angiogenesis: Involvement of p38 mitogen-activated protein kinase. Hypertens Res 2008;31:2085-2096.
60. Maddika S, Panigrahi S, Wiechec E, et al. Unscheduled Akt-triggered activation of cyclin-dependent kinase 2 as a key effector mechanism of apoptin's anticancer toxicity. Mol Cell Biol 2009;29:1235-1248.
61. Zhang R, Banik NL, Ray SK. Combination of all-trans retinoic acid and interferon-gamma upregulated p27(kip1) and down regulated CDK2 to cause cell cycle arrest leading to differentiation and apoptosis in human glioblastoma LN18 (PTEN-proficient) and U87MG (PTEN-deficient) cells. Cancer Chemother Pharmacol 2008;62:407-416.
62. Wang P, Ma Q, Luo J, et al. Nkx3.1 and p27(KIP1) cooperate in proliferation inhibition and apoptosis induction in human androgen-independent prostate cancer cells. Cancer Invest 2009;27:369-375.
63. Munoz-Alonso MJ, Gonzalez-Santiago L, Zarich N, et al. Plitidepsin has a dual effect inhibiting cell cycle and inducing apoptosis via Rac1/c-Jun NH2-terminal kinase activation in human melanoma cells. J Pharmacol Exp Ther 2008;324:1093-1101.
64. Xie XH, An HJ, Kang S, et al. Loss of Cyclin B1 followed by downregulation of Cyclin A/Cdk2, apoptosis and antiproliferation in Hela cell line. Int J Cancer 2005;116:520-525.
65. Yuan J, Yan R, Kramer A, et al. Cyclin B1 depletion inhibits proliferation and induces apoptosis in human tumor cells. Oncogene 2004;23:5843-5852.
66. Yang YC, Tsao YP, Ho TC, Choung IP. Peroxisome proliferator-activated receptor-gamma agonists cause growth arrest and apoptosis in human ovarian carcinoma cell lines. Int J Gynecol Cancer 2007;17:418-425.
67. Liou JY, Wu CC, Chen BR, Yen LB, Wu KK. Nonsteroidal anti-inflammatory drugs induced endothelial apoptosis by perturbing peroxisome proliferator-activated receptor-delta transcriptional pathway. Mol Pharmacol 2008;74:1399-1406.
68. Naito Y, Takagi T, Matsuyama K, Yoshida N, Yoshikawa T. Pioglitazone, a specific PPAR-gamma ligand, inhibits aspirin-induced gastric mucosal injury in rats. Aliment Pharmacol Ther 2001;15:865-873.